AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02135380 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard Therapy
Study NCT02127255 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual acupuncture implemented by acupuncturist 1
Description: Manual acupuncture once per day. Acupuncture treatment regimens (acupoints, needling methods, needle retention time) were decided by acupuncturist 1 according to the syndrome differentiation of patients. Acupuncturist 1 has to have more than 15 years of acupuncture clinical practice experience.
Study NCT02127255 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual acupuncture implemented by acupuncturist 2
Description: Manual acupuncture given by acupuncturist 2 once per day. Acupuncture treatment regimens (acupoints, needling methods, needle retention time) were decided by acupuncturist 1 according to the syndrome differentiation of patients. Acupuncturist 2 has to have less than 5 years of acupuncture clinical practice experience.
Study NCT02363075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamfetamine sulphate
Description: 10mg/day per os for the first ten days, 20mg/day for the ten following days, 30mg/day until D90.
Study NCT02363075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 10mg/day per os for the first ten days, 20mg/day for the ten following days, 30mg/day until D90.
Study NCT00631137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: testosterone gel applied to skin
Description: Application of testosterone gel
Study NCT00631137 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: whey powder protein
Study NCT03668509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1459
Description: oral adminstration, single dose
Study NCT02537288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedovapagon
Study NCT03137615 — intervention group
Intervention type: PROCEDURE
Intervention: Pituitary surgery
Description: Trans-sphenoidal resection of a pituitary gland lesion.
Study NCT03137615 — intervention group
Intervention type: DRUG
Intervention: local anaesthetic injection
Description: The surgeon infiltrates the nasal septum with local anaesthesia as per usual practice. This consists of Moffet's solution and lidocaine with adrenaline (1:200,000).
Study NCT03891147 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Study NCT04479904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: po
Study NCT00996203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg iv every 4 weeks for 24 weeks
Study NCT01417390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Gemcitabine and cisplatin
Description: Patients receive Gemcitabine (1000mg/m2 on day 1,8) and cisplatin (20mg/m2 on day 1-4) every three weeks for two cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (40mg/m2) every week for six cycles during radiotherapy.
Study NCT01417390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Patients receive radical radiotherapy and cisplatin (40mg/m2) every week for six cycles during radiotherapy
Study NCT00996203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMARDs (disease-modifying antirheumatic drugs)
Description: stable doses at investigator's prescription
Study NCT01740180 — intervention group
Intervention type: OTHER
Intervention: Data entry
Description: This cohort describes the basic information about the patients (age, sex, weight, height, background) as well as acts required, treatment and results of imaging studies.~These data are extracted from patient records by each participating center and collected in an e-CRF.
Study NCT02401334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cook® Antimicrobial Hernia Repair Device
Description: Device containing an antimicrobial to reinforce soft tissue during ventral or incisional hernia repair in clean-contaminated, contaminated, and dirty-infected
Study NCT04004091 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Spermine
Description: Spermine is a polyamine. It is an organic molecule that is involved in cellular metabolism and development.
Study NCT02733120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stable isotope infusion
Description: stable isotopes such as 15N2, TRP, 2H3-Leucine, L-\[2H3\]-3-Methylhistidine, 2H2-Glycine, 2-D-hydroxyproline, 1-13C-ketoisocaproic acid (KIC), L-\[Guanido-15N2\]-Arginine, L-\[ureido-13C-2H2\]-Citrulline), L-Glutamine-amide-15N, 1,2-13C2-L-Glutamic acid, 1,2-13C2Taurine, and 13C-Urea is given IV simultaneously
Study NCT03787589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Prescription
Description: Participants in the intervention group will be given an exercise prescription to increase their baseline steps by 1200 and 2000 steps per day at least 3 days a week over the first 3 months. If tolerated and accepted, the participants will increase their step counts by an additional 600 to 1000 steps per day at least 3 days a week for the next 3 months.This will be followed by a 6-month maintenance phase. The research coordinator will instruct the participants on the proper use of the Nordic walking poles which can be used to help participants achieve their prescribed number of steps.~All participants will be encouraged to wear the pedometer throughout the trial in order to follow the step-count prescription and monitor adherence.
Study NCT00848120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8mg/kg iv every 4 weeks for 24 weeks
Study NCT02344225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine citrate
Description: Caffeine citrate IV (20 mg/kg loading dose, 5 mg/kg/day maintenance dose)
Study NCT02537288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Study NCT02537288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for fedovapagon)
Study NCT02344225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen (10 mg/kg loading dose followed by low dose ibuprofen 2.5 mg/kg/day) for 5 days
Study NCT02344225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Ketorolac (Acuvail) eye drops (one drop two times a day) for 14 days
Study NCT00772447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: 4mg/kg IV ; Q 24 hr (once every 24 hours)
Study NCT00772447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin - 1g per 12 hrs, for 7-14 days~Or switch to~Vancomycin Followed by Semi-synthetic Penicillin-Cloxacillin:~- 1 g every 6 hours or 2 g every 8 hours
Study NCT01951677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBsAg
Description: Standard hepatitis B vaccine antigen
Study NCT01951677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HBsAg
Description: Standard hepatitis B vaccine antigen
Study NCT00183794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel and Gemcitabine
Description: Docetaxel 75 mg/m2 IV over 15-30 minutes on day 1 followed by Gemcitabine 800 mg/m2 IV over 30 minutes on Days 1 and 8 of each 3 weeks (21 days) cycle.
Study NCT02183415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 BS, low dose
Study NCT02183415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 BS, medium dose
Study NCT02183415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 BS, high dose
Study NCT02183415 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02592226 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anesthesia: alveolar recruitment maneuver
Study NCT02592226 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anesthesia: standardized
Study NCT01851733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI-guided Laser Heat Ablation (MLA)
Study NCT01951677 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PreS HBsAg
Description: preS hepatitis B surface antigen
Study NCT01951677 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PreS HBsAg
Description: preS hepatitis B surface antigen
Study NCT01951677 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Advax-1(TM)
Description: Adjuvant formulated with vaccine antigen
Study NCT01951677 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Advax-2(TM)
Description: Adjuvant formulated with vaccine antigen
Study NCT01951677 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Advax-3(TM)
Description: Adjuvant formulated with vaccine antigen
Study NCT01951677 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Alum
Description: Adjuvant formulated with vaccine antigen
Study NCT04502303 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FDG and 68Ga-FAPI PET/CT
Description: Participants will undergo 18F-FDG (0.12-0.15mCi/kg) and 68Ga-FAPI (3-6mCi) PET/CT on two consecutive days. At least 6 hours of fast is required for 18F-FDG PET scan, while no dietary control is necessary for 68Ga-FAPI PET scan. If the patients are on metformin, discontinuation of 48 hours is required before 18F-FDG injection to minimize the bowel uptake. If the patient is planned for surgical resection of one or more stricture (s), the scans have to be completed within a maximum period of 30 days before the surgery.
Study NCT02844998 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: patients will do moderate running which make them breathe somewhat harder than normal for at least 30 minutes for 5 days in a week
Study NCT02844998 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: physical activity
Description: patients will do moderate running which make them breathe somewhat harder than normal for at least 30 minutes for 5 days in a week
Study NCT02844998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dapoxetine 30 mg on demand
Description: Dapoxetine, a short-acting selective serotonin reuptake inhibitors, has been utilized for the treatment of premature ejaculation in various countries
Study NCT03094195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMA401
Description: EMA401
Study NCT03094195 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00529737 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast Biopsy
Description: Stereotactic-guided breast biopsy via standard practice of care
Study NCT00529737 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post Procedure Mammogram
Description: View of post-procedure mammogram same projection as used in the biopsy procedure (View A), and mammographic view orthogonal projection to the first view (View B).
Study NCT00360399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram 10 to 20 mg per day for 12 weeks
Study NCT00360399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Duloxetine 30 to 60 mg per day for 12 weeks
Study NCT00360399 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Description: CBT will include 16 one-hour sessions provided over 12 weeks.
Study NCT03016780 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplantation
Description: Fecal microbiota transplantation and the traditional treatments for ulcerative colitis in part 1.
Study NCT03016780 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline and the traditional treatments for ulcerative colitisin in part 2.
Study NCT04553107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deprescribing Intervention
Description: An individualized deprescribing intervention will be created by a pharmacist working with a patient to identify harmful, costly, and unnecessary medications to be reduced. The intervention will include a plan and monitoring for up to 3 months to reduce medication use.
Study NCT04553107 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The usual care arm will receive the current standard of care, which includes medication reconciliation by a clinic nurse at the time of their appointment. Nurses review all medications and answer medication-related questions, and refer medication questions to the healthcare provider for further discussion when necessary.
Study NCT01497262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Fingolimod will be supplied as 0.5mg capsules in bottles of 35.
Study NCT03005626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic education
Study NCT03005626 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard follow-up
Study NCT03004807 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Centrum Silver Mens' Formula
Description: Multivitamin/Multimineral dietary supplement produced for Pfizer for use in older men.
Study NCT03004807 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: A matching tablet to the dietary supplement, but without any active ingredients
Study NCT05610371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: The study group underwent hysteroscopy using saline to which 10ml of 2% lidocaine was added to the first 1000 ml. This dose of lidocaine was calculated to allow maximal benefits with minimal potential complications. The maximal dose of lidocaine is 5mg\\kg in adults which translates to 200mg in a 40kg patient. We have set 200 mg as the maximal dose of lidocaine in our study, assuring the dosage is safe. The rest of the procedure following the first 1000ml of saline was completed using saline alone as needed.
Study NCT05610371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: The control group underwent hysteroscopy using a saline distension medium.
Study NCT05610371 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The control group underwent hysteroscopy using a saline distension medium.
Study NCT01752023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin + Gemcitabine with SUBATM-itraconazole
Description: Experimental Arm
Study NCT01752023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin + Gemcitabine
Description: Active Comparator
Study NCT04112680 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Debunking Misinformation through Audio Dramas
Description: The audio dramas (one drama of 4 episodes per intervention group), aim to debunk misinformation about an infectious disease. The content of the two dramas differ in the two groups; in intervention group 1, the drama will state the misinformation and provide a plausible alternative, delivered through a trusted source, in line with world views. In intervention group 2, the audio drama will avoid mentioning the misinformation and instead only state the correct information about the infectious disease
Study NCT04112680 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group audio jingles
Description: The control group will receive audio jingles about exclusive breastfeeding
Study NCT02445833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle on-line intervention
Description: The self-applied on-line intervention will comprise a behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating habits and physical activity in participants (Themes: 1.motivation for change; 2. nutrition and physical activity education; 3. barriers to change, healthy eating principles and how to be active; 4. Influence of thoughts; 5. Emotional eating and self-control; 6. Problem solving; 7. Body image and assertiveness; 8. Relapse prevention)..The program will be established as follows: The first day the participant log in the website where can access the processing modules. A web page was developed specially for this study.
Study NCT05535179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: honeysuckle and semen oroxyli solution
Description: The patients in the treatment group were instructed to gargle the solution containing honeysuckle and semen oroxyli (25 mL) four times a day for 2 weeks.
Study NCT03845387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KDT-3594
Description: oral administration, dose titration
Study NCT03845387 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pramipexole
Description: ER formulation, oral administration, dose titration
Study NCT05190952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine 0.25% 1ml/kg will be injected subcutaneously by the surgeon before wound closure.
Study NCT05190952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: In addition to bupivacaine, ketamine 1mg/kg diluted in 10 ml normal saline will be injected subcutaneously by the surgeon before wound closure. Bupivacaine and ketamine will be administered using two separate syringes.
Study NCT05190952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: In addition to bupivacaine, dexamethasone 0.2mg/kg diluted in 10 ml normal saline will be injected subcutaneously by the surgeon before wound closure. Bupivacaine and dexamethsone will be administered using two separate syringes.
Study NCT02787772 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Elective Hernia repair
Description: abdominal wall hernia repair using onlay mesh.
Study NCT03871478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: See Arm Description
Study NCT03871478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: See Arm Description
Study NCT03871478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine and Bupivacaine
Description: See Arm Description
Study NCT02567526 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Between-Meal Intervention Group
Description: Non-nursing staff trained as Feeding Assistants were responsible for supplement and snack delivery in the mornings and afternoons between meals supervised by research staff
Study NCT01597102 — intervention group
Intervention type: OTHER
Intervention: No interventions
Description: No intervention is planned in this study
Study NCT03644160 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity and behaviour change
Description: The intervention group (group A) will receive an 8 week individualised, tailored behaviour change intervention to promote PA and an information booklet about physical activity to include an initial 1:1 session with a physiotherapist with training in behaviour change techniques and motivational interviewing. Using a range of behaviour change and self-regulation techniques (eg goal-setting, self-monitoring), participants will be guided towards physical activity maintenance at the end of the 8 weeks. In addition, participants will be signposted to physical activity classes, facilities and resources in the local community. This group will continue with their routine care for their condition throughout the study period.
Study NCT02667145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self care program focusing on the assistive device
Description: self-heed program focusing on the assistive device will consist of four weekly meetings lasting approximately 90 minutes. it will be stimulated the self-heed through knowledge of pathology and guidelines of protection articulate, and will be supplied, and trained the use of assistive devices to improve the performance of volunteers in their daily activities. Assistive devices are devices, not attached to the body, which help people with limited movements and restrictions on participation in the activities of everyday life. Example: thickening of tableware, tin openers. These volunteers will be evaluated in three stages: 1-initial assessment 2-after completion of the program and 90 days after the initial assessment. The questionnaires that will be used are: EVA; SACRAH; COPM; WHOQOL-Bref.
Study NCT01145937 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET
Description: Partial Endothelial Trepanation in addition to an anterior lamellar keratoplasty
Study NCT01145937 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DALK
Description: Conventional DALK grafting procedure, with Big Bubble technique according to Anwar et al.
Study NCT04555941 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: intermittent theta burst stimulation
Description: active or Sham iTBS will be given to the AD/MCI patient
Study NCT04555941 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation
Description: active or Sham iTBS will be given to the AD/MCI patient
Study NCT04523532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary folate and hazelnut oil
Description: Intervention with folate-rich diet and hazelnut oil supplement in capsule
Study NCT04523532 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary folate and hazelnut oil
Description: Intervention with folate-rich diet and hazelnut oil supplement in capsule